期刊
INTERNATIONAL JOURNAL OF HEMATOLOGY
卷 107, 期 3, 页码 286-296出版社
SPRINGER JAPAN KK
DOI: 10.1007/s12185-017-2346-6
关键词
Doxorubicin; Mesenchymal stem cells; Stress-induced premature senescence; gamma-H2AX foci
类别
资金
- Russian Science Foundation [14-50-00068]
- Russian Science Foundation [14-50-00068] Funding Source: Russian Science Foundation
Doxorubicin (Dox) is an effective anticancer drug with known activity against a wide spectrum of malignancies, hematologic malignancies in particular. Despite extensive clinical use, the mechanisms of its side effects and negative action on normal cells remain under study. The aim of this study was to investigate the effect of Dox on cultured human mesenchymal stem cells (MSCs) derived from menstrual blood (eMSCs), bone marrow (BMSCs) and adipose tissue (AMSCs). Dox treatment in high doses decreased the survival of MSCs in a dose-dependent manner. Clinically relevant low doses of Dox induced premature senescence of eMSCs, BMSCs and AMSCs, but did not kill the cells. Dox caused cell cycle arrest and formation of gamma-H2AX foci, and increased the number of SA-beta-gal-positive cells. BMSCs entered premature senescence earlier than other MSCs. It has been reported that neural-like cells differentiated from MSCs of various origins are more sensitive to Dox than their parent cells. Dox-treated differentiated MSCs exhibited lower viability and earlier generation of gamma-H2AX foci. Dox administration inhibited secretory activity in neural-like cells. These findings suggest that a clinically relevant Dox dose damages cultured MSCs, inducing their premature senescence. MSCs are more resistant to this damage than differentiated cells.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据